IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial

IDEAYA Biosciences (NASDAQ: IDYA) announced investor events and updated timing guidance for topline results from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma.

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced investor events and updated timing guidance for topline results from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma. The company projects a database lock in the first half of April, followed by topline data analysis and a live investor webcast.

Management will host live webcasts and fireside chats at Bank of America Merrill Lynch (May 12, 2026) and Stifel Targeted Oncology Virtual Forum (May 19, 2026); replays will be available for 30 days and preregistration will be provided on IDEAYA's investor events page.

Positive

• Database lock projected in the first half of April
• Topline data analysis to follow immediately after database lock
• Live investor webcast planned to present topline results and Q&A

Negative

• None.

Argus Mar 23 session

-3.39% close to close Open Argus

Details

News Market Reaction – IDYA

On Mar 23, the first trading day after this news, IDYA closed 3.39% below the previous close.

Data tracked by StockTitan Argus for the Mar 23 session.

Key Figures

Database lock timing: First half of April BofA conference date: May 12, 2026 Stifel forum date: May 19, 2026 +1 more

Database lock timing

First half of April

Projected database lock for OptimUM-02 darovasertib trial

BofA conference date

May 12, 2026

Bank of America Merrill Lynch Health Care Conference fireside chat

Stifel forum date

May 19, 2026

Stifel 2026 Targeted Oncology Virtual Forum fireside chat

Webcast replay window

30 days

Replay availability following live investor webcasts

Previous Conferences,clinical trial Reports

3 past events · Latest: Aug 29

Same Type 3 events

1. Aug 29

   Darovasertib OS data

   24h Move

   -1.5%

   Announced first median overall survival data for darovasertib/crizotinib in mUM.

2. Jul 23

   R&D day announcement

   24h Move

   +7.3%

   Planned R&D Day to present multiple clinical data updates and strategy.

3. Jul 05

   IDE397 data webcast

   24h Move

   +15.3%

   Scheduled investor webcast to report Phase 2 IDE397 monotherapy data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 2/3, topline data, database lock, hla-a2*-negative, +2 more

6 terms

phase 2/3 medical

"topline data release from the Phase 2/3 OptimUM-02 trial in first-line..."

A phase 2/3 trial is a combined clinical study that first evaluates how well a treatment works and the best dose, then expands into a larger test to confirm those results and safety. For investors, it matters because moving into a phase 2/3 signals that an experimental therapy has shown initial promise and will be tested at scale, which can materially change the odds and timeline for regulatory approval and commercial potential.

topline data technical

"updated guidance related to the timing of its upcoming topline data release..."

Topline data are the initial, high-level results from a clinical study that show whether the main goals of the trial were met, much like the headline of a news story that summarizes the most important point. Investors care because these early outcomes quickly indicate a drug’s commercial potential and regulatory path — positive topline results can boost a company’s value, while disappointing ones can sharply reduce expected future revenue.

database lock technical

"The database lock is projected in the first half of April..."

A database lock is the point in a clinical trial when the collected study data are finalized and no further changes or corrections are allowed, so analysts can run the official statistical tests. For investors this matters because it usually precedes public results or regulatory filings—think of it like sealing and signing off an exam before grading: once locked, the timing and content of the readout become clearer and uncertainty about last-minute data edits is reduced.

hla-a2*-negative medical

"trial in first-line HLA-A2*-negative metastatic uveal melanoma."

HLA-A2*-negative means a person does not carry the HLA‑A2 version of a common immune system protein used to show bits of viruses or tumors to immune cells. For investors, this matters because many immune-based drugs, vaccines or cell therapies are designed to work only in people who have specific HLA types; being HLA‑A2 negative is like not having the matching lock for a drug’s key, which can limit who can benefit or be enrolled in trials.

metastatic uveal melanoma medical

"trial in first-line HLA-A2*-negative metastatic uveal melanoma."

Metastatic uveal melanoma is an eye cancer that begins in the uvea (the eye’s middle layer) and has spread to other parts of the body, most often the liver. For investors, it matters because the spread makes the disease much harder to treat, so clinical trial results, regulatory approvals, and new therapies can dramatically change a drug developer’s prospects—think of a small house fire that spreads to the whole neighborhood, changing the value of nearby properties.

key opinion leader medical

"webcast will be hosted by IDEAYA management and a guest key opinion leader"

A key opinion leader is an individual whose insights, expertise, or influence significantly shape the opinions and decisions of others within a particular field or community. For investors, they are like trusted guides whose views can impact market trends or perceptions, making their perspectives important to watch. Their influence often stems from experience, reputation, or widespread respect among peers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., March 22, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events and provided updated guidance related to the timing of its upcoming topline data release from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma.

Darovasertib Phase 2/3 OptimUM-02 Trial Topline Results Investor and Analyst Webcast:

• Updated Topline Results Guidance: The database lock is projected in the first half of April, followed by the topline data analysis thereafter
• Live investor and analyst webcast will be hosted by IDEAYA management and a guest key opinion leader
• Pre-registration will be available prior to the event through IDEAYA's investor relations events page at https://ir.ideayabio.com/events

Bank of America Merrill Lynch Health Care Conference
Tuesday, May 12^th, 2026

• Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Bank of America

Stifel 2026 Targeted Oncology Virtual Forum
Tuesday, May 19^th, 2026

• Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Laura Prendergast, Managing Director, PhD

A live audio webcast of the events will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live events.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.  Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications.  Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the expected timing of database lock, analysis and topline results from the Phase 2/3 OptimUM-02 trial; the anticipated timing and content of and participation in and/or presentation at investor and analyst events and webcasts; and IDEAYA's expectations regarding its clinical development activities.  Forward-looking statements are based on IDEAYA's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to the timing, progress, and results of clinical trials, including the OptimUM-02 trial; the timing of data readouts, database analysis; the risk that topline results may not be predictive of final results; the potential for delays in clinical development; regulatory developments; and other risks described in IDEAYA's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.  IDEAYA undertakes no obligation to update or revise any forward-looking statements, except as required by law.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-upcoming-investor-relations-events-and-updated-darovasertib-topline-results-guidance-from-phase-23-optimum-02-trial-302721438.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will IDEAYA (IDYA) report topline results from the OptimUM-02 trial?

IDEAYA projects a database lock in the first half of April, then will analyze topline data. According to the company, analysis will follow the database lock and topline results will be presented in a live investor webcast thereafter.

How can investors access IDEAYA's (IDYA) topline results webcast and replay?

A live webcast will present the topline results, with a replay available for 30 days. According to the company, preregistration will be available on IDEAYA's investor events page and webcasts will also appear under the Investors/Events section.

What investor events will IDEAYA (IDYA) management attend in May 2026?

IDEAYA will appear at Bank of America Health Care Conference on May 12, 2026 and Stifel Targeted Oncology Virtual Forum on May 19, 2026. According to the company, both events include fireside chats with CEO Yujiro S. Hata.

Will IDEAYA (IDYA) provide a replay of the OptimUM-02 topline event and for how long?

Yes; a replay of the webcast will be accessible for 30 days after the live event. According to the company, the replay will be posted under the Investors/Events section of IDEAYA's website or via the conference host.

What patient population does the OptimUM-02 Phase 2/3 trial for darovasertib target?

The OptimUM-02 trial targets first-line HLA-A2*-negative metastatic uveal melanoma patients. According to the company, the topline data relate specifically to this patient population and will be addressed during the webcast.